Risk Factor of Proteinuria in Patients Receiving Ramucirumab-Reference-Cited by-同舟云学术

Risk Factor of Proteinuria in Patients Receiving Ramucirumab

Published:2021-05-10 Issue:5 Volume:47 Page:250-255
ISSN:1346-342X
Container-title:Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)
language:en
Short-container-title:Jpn. J. Pharm. Health Care Sci.

Author:

Tanaka Tomoya¹,Kurata Yasuko²,Takase Naotake¹,Himoto Mayuko¹,Shinmen Toru¹,Dan Kazuki¹,Kajizono Makoto²,Masaoka Yasuyuki²,Nakamoto Akihiko²,Nawa Hideki³,Kitamura Yoshihisa³,Ikesue Hiroaki⁴,Muroi Nobuyuki⁴,Sendo Toshiaki²,Miki Ikuko¹

Affiliation:

1. Department of Pharmacy, Ako City Hospital

2. Department of Pharmacy, Okayama University Hospital

3. School of Pharmacy, Shujitsu University

4. Department of Pharmacy, Kobe City Medical Center General Hospital

Publisher

Japanese Society of Pharmaceutical Health Care and Sciences

Subject

General Earth and Planetary Sciences,General Environmental Science

Link

https://www.jstage.jst.go.jp/article/jjphcs/47/5/47_250/_pdf

Reference10 articles.

1. 1）Spratlin JL, Cohen RB, Eadens M, Gore L, Camidge DR, Diab S, Leong S, O’Bryant C, Chow LQ, Serkova NJ, Meropol NJ, Lewis NL, Chiorean EG, Fox F, Youssoufian H, Rowinsky EK, Eckhardt SG, Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2, J Clin Oncol, 2010, 28, 780-787.

2. 2）Chen HX, Cleck JN, Adverse effects of anticancer agents that target the VEGF pathway, Nat Rev Clin Oncol, 2009, 6, 465-477.

3. 3）日本腎臓病学会, 日本癌治療学会, 日本臨床腫瘍学会, 日本腎臓病薬物療法学会編, “がん薬物療法時の腎障害診療ガイドライン2016”, ライフサイエンス社, 東京, 2016, pp34-35.

4. 4）Kanbayashi Y, Ishikawa T, Tabuchi Y, Sakaguchi K, Ouchi Y, Otsuji E, Takayama K, Taguchi T, Predictive factors for the development of proteinuria in cancer patients treated with bevacizumab, ramucirumab, and aflibercept: a single-institution retrospective analysis, Sci Rep, 2020, 10, 2011. doi: 10.1038/s41598-020-58994-5.

5. 5）Hirai T, Shuji Y, Takiyama M, Hanada K, Itoh T, Renin-angiotensin system inhibitors for countering proteinuria induced by angiogenesis inhibitors: A retrospective observational analysis, Cancer Chemother Pharmacol, 2019, 84, 195-202.